Search

Your search keyword '"Fanelli, F"' showing total 10 results
Start Over Author "Fanelli, F" Journal digestive and liver disease
10 results on '"Fanelli, F"'

1. BOC.02.4: EPISODIC OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT DOES NOT INCREASE MORTALITY IN PATIENTS WITH CIRRHOSIS

Author

Nardelli, S., primary, Riggio, O., additional, Marra, F., additional, Gioia, S., additional, Saltini, D., additional, Bellafante, D., additional, Adotti, V., additional, Guasconi, T., additional, Ridola, L., additional, Rosi, M., additional, Caporali, C., additional, Fanelli, F., additional, Roccarina, D., additional, Bianchini, M., additional, Indulti, F., additional, Spagnoli, A., additional, Merli, M., additional, Vizzutti, F., additional, and Schepis, F., additional

Published
2024
Full Text
View/download PDF

2. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis

Author

Nardelli, S., primary, Riggio, O., additional, Marra, F., additional, Gioia, S., additional, Saltini, D., additional, Bellafante, D., additional, Adotti, V., additional, Guasconi, T., additional, Ridola, L., additional, Rosi, M., additional, Caporali, C., additional, Fanelli, F., additional, Roccarina, D., additional, Bianchini, M., additional, Indulti, F., additional, Spagnoli, A., additional, Merli, M., additional, Vizzutti, F., additional, and Schepis, F., additional

Published
2024
Full Text
View/download PDF

3. Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.

Author

Roccarina, D., primary, Turco, L., additional, Campani, C., additional, Saltini, D., additional, Aspite, S., additional, Calvaruso, V., additional, Arena, U., additional, Senzolo, M., additional, Fanelli, F., additional, Caporali, C., additional, Gitto, S., additional, Citone, M., additional, Di Bonaventura, C., additional, Schepis, F., additional, Vizzutti, F., additional, Riggio, O., additional, Burra, P., additional, Villa, E., additional, Cammà, C., additional, Marra, F., additional, and Bianchini, M., additional

Published
2022
Full Text
View/download PDF

10. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study

Author

Pietro Andreone, Silvia Aspite, Claudia Campani, Francesco Vizzutti, Fabio Marra, Pasquale Apolito, Sinan Sadalla, Filippo Schepis, A. Scuteri, Laura Turco, Stefano Gitto, Fabio Conti, Giacomo Laffi, Federica Lombardo, Umberto Arena, Giovanni Vitale, Erica Villa, Fabrizio Fanelli, W. Debernardi-Venon, Gitto S., Vizzutti F., Schepis F., Turco L., Aspite S., Vitale G., Arena U., Villa E., Laffi G., Debernardi-Venon W., Fanelli F., Andreone P., Marra F., Apolito P., Campani C., Sadalla S., Lombardo F., Conti F., and Scuteri A.

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis complication, medicine.medical_treatment, Kaplan-Meier Estimate, Antiviral therapy, Advanced liver disease, Cirrhosis complications, Portal hypertension, Hepatology, Gastroenterology, Logistic regression, Antiviral Agents, Severity of Illness Index, End Stage Liver Disease, 03 medical and health sciences, Liver disease, Postoperative Complications, 0302 clinical medicine, Internal medicine, Hypertension, Portal, medicine, Humans, Adverse effect, Aged, Univariate analysis, business.industry, Case-control study, Middle Aged, medicine.disease, Hepatitis C, Logistic Models, Treatment Outcome, Italy, Case-Control Studies, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Portasystemic Shunt, Transjugular Intrahepatic, business, Transjugular intrahepatic portosystemic shunt
Abstract

Background Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a well-established treatment for complications of portal hypertension. Aims To analyze the impact of TIPS on virologic response and safety profile in patients treated with direct-acting antivirals (DAAs). Methods We analyzed data from HCV-positive cirrhotic patients treated with DAAs. Twenty-one patients with previous TIPS placement were compared with 42 matched subjects without TIPS. Logistic regression was used to identify predictors of hepatic function worsening and adverse events. Results No differences were found between the two groups in particular regarding sustained virologic response (92.5 and 97.6% in TIPS vs no-TIPS, p = 0.559). Model for End-stage Liver Disease (MELD) of both TIPS and no-TIPS groups declined from baseline to week 24 of follow-up (from 12.5 ± 3.5 to 10.8 ± 3.4 and from 11.1 ± 3.5 to 10.3 ± 3.4, p = 0.044 and 0.025). There were no differences in adverse event rates. At univariate analysis, age was associated with MELD increase from baseline to week 24 (OR 1.111, 95% CI 1.019-1.211, p = 0.017), and patients with higher baseline MELD developed serious adverse events more frequently (OR 0.815, 95% CI 0.658–1.010, p = 0.062). Patients with or without TIPS did not show differences in transplant-free survival. Conclusion TIPS placement does not affect virologic response and clinical outcome of patients receiving DAAs.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results